Cleveland Stock Story

CBLI -  USA Stock  

USD 3.94  0.36  8.37%

While some millenniums are indifferent towards healthcare space, it makes sense to concentrate on Cleveland Biolabs. Why are we still confident in anticipation of a complete recovery. Is Cleveland Biolabs valuation sustainable? Here I will cover a perspective on valuation of Cleveland to give you a better outlook on taking a position in this stock.
Published over three months ago
View all stories for Cleveland Biolabs | View All Stories
Will Cleveland Biolabs (NASDAQ:CBLI) price increase in May 2021?
The current Long Term Debt to Equity is estimated to decrease to 0.0138. The current Debt to Equity Ratio is estimated to decrease to -0.11
We provide trade advice to complement the prevailing expert consensus on Cleveland Biolabs. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
We determine the current worth of Cleveland Biolabs using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Cleveland Biolabs based exclusively on its fundamental and basic technical indicators. By analyzing Cleveland Biolabs's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Cleveland Biolabs's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cleveland Biolabs. We calculate exposure to Cleveland Biolabs's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Cleveland Biolabs's related companies.

Cleveland Biolabs Investment Alerts

Cleveland investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Cleveland Biolabs performance across your portfolios.Please check all investment alerts for Cleveland

Cleveland Biolabs Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Cleveland value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cleveland Biolabs competition to find correlations between indicators driving the intrinsic value of Cleveland.

How Cleveland utilizes its cash?

To perform a cash flow analysis of Cleveland Biolabs, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Cleveland Biolabs is receiving and how much cash it distributes out in a given period. The Cleveland Biolabs cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Cleveland Biolabs Net Cash Flow from Operations is most likely to increase significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (2.37 Million)

Acquisition by Buckheit Robert of 24378 shares of Cleveland Biolabs subject to Rule 16b-3

Legal trades by Cleveland Biolabs insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Cleveland insider trading alert for grant of common stock par value $0.005 per share by Buckheit Robert, Chief Technology Officer, on 29th of July 2021. This event was filed by Cytocom Inc with SEC on 2021-07-29. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

An Additional Perspective On Cleveland Biolabs

This firm reported the previous year's revenue of 262.94 K. Net Loss for the year was (2.4 M) with loss before overhead, payroll, taxes, and interest of (428.13 K).
 2020 2021 (projected)
Interest Expense980.62 K974.89 K
Gross Profit262.94 K269.86 K

Margins Breakdown

Cleveland profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Cleveland Biolabs itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Cleveland Biolabs profit margins.
Operating Margin(68.01)
EBITDA Margin(9.31)
Gross Margin0.89
Profit Margin(9.36)


Cleveland Biolabs Earnings Before Interest Taxes and Depreciation Amortization EBITDA is nearly stable at the moment. Also, Cleveland Biolabs Revenue Per Employee is decreasing over the last 8 years.

Our perspective of the current Cleveland Biolabs rise

Current treynor ratio is at 0.55. Cleveland Biolabs is displaying above-average volatility over the selected time horizon. Investors should scrutinize Cleveland Biolabs independently to ensure intended market timing strategies are aligned with expectations about Cleveland Biolabs volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cleveland Biolabs' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cleveland Biolabs' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Conclusion on Cleveland Biolabs

While some firms within the biotechnology industry are still a little expensive, even after the recent corrections, Cleveland Biolabs may offer a potential longer-term growth to stockholders. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither acquire new shares of Cleveland nor quit your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Cleveland Biolabs.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Cleveland Biolabs. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com